U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Stage IIA Cervical Cancer FIGO 2018

MedGen UID:
1705356
•Concept ID:
C5206444
•
Neoplastic Process
Synonym: Stage IIA Cervical Carcinoma FIGO 2018

Definition

Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement. (FIGO 2018) [from NCI]

Professional guidelines

PubMed

Establishment of a risk stratification model based on the combination of post-treatment serum squamous cell carcinoma antigen levels and FIGO stage of cervical cancer for treatment and surveillance decision-making.
Shi L, Liu Y, Li J, Kou J, Ouyang Y, Chen F, Huang X, Huo L, Huang L, Cao X
J Cancer Res Clin Oncol 2023 Aug;149(9):5999-6007. Epub 2023 Jan 9 doi: 10.1007/s00432-022-04558-1. PMID: 36624190Free PMC Article
Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer.
Maene C, Salihi RR, Van Nieuwenhuysen E, Han SN, Concin N, Vergote I
Int J Gynecol Cancer 2021 Jun;31(6):824-828. Epub 2021 Apr 15 doi: 10.1136/ijgc-2021-002432. PMID: 33858952
Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer.
Chong GO, Lee YH, Han HS, Lee HJ, Park JY, Hong DG, Lee YS, Cho YL
Gynecol Oncol 2018 Jan;148(1):97-102. Epub 2017 Nov 15 doi: 10.1016/j.ygyno.2017.11.003. PMID: 29153540

Recent clinical studies

Etiology

Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study.
Duan H, Li H, Kang S, Zhao H, Chen B, Wang L, Li P, Wang Y, Wang W, Lang J, Liu P, Chen C
Acta Obstet Gynecol Scand 2023 Aug;102(8):1045-1052. Epub 2023 Jun 20 doi: 10.1111/aogs.14612. PMID: 37338046Free PMC Article
Prognostic factors of 2018 FIGO stage IB-IIA cervical cancer with absence of high/ intermediate surgical-pathological risk factors.
Shibuya Y, Shimada M, Tsuji K, Shigeta S, Tanase Y, Matsuo K, Yamaguchi S, Kanao H, Saito T, Mikami M
Jpn J Clin Oncol 2022 Nov 3;52(11):1289-1296. doi: 10.1093/jjco/hyac125. PMID: 35913375
Preoperative high-dose-rate brachytherapy for high-risk early-stage cervical cancer: Long-term clinical outcome analysis.
Gauci PA, Kee DLC, Thamphya B, Schiappa R, Delotte J, Chand-Fouche ME, Hannoun-Levi JM
Brachytherapy 2022 May-Jun;21(3):273-282. Epub 2022 Jan 31 doi: 10.1016/j.brachy.2021.11.007. PMID: 35094933
Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer.
Jiang Y, Gu H, Zheng X, Pan B, Liu P, Zheng M
Pathol Oncol Res 2021;27:1609946. Epub 2021 Dec 21 doi: 10.3389/pore.2021.1609946. PMID: 34992504Free PMC Article
Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.
Huang H, Feng YL, Wan T, Zhang YN, Cao XP, Huang YW, Xiong Y, Huang X, Zheng M, Li YF, Li JD, Chen GD, Li H, Chen YL, Ma LG, Yang HY, Li L, Yao SZ, Ye WJ, Tu H, Huang QD, Liang LZ, Liu FY, Liu Q, Liu JH
JAMA Oncol 2021 Mar 1;7(3):361-369. doi: 10.1001/jamaoncol.2020.7168. PMID: 33443541Free PMC Article

Diagnosis

The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
van Kol KGG, Ebisch RMF, van der Aa M, Wenzel HB, Piek JMJ, Bekkers RLM
Gynecol Oncol 2023 Apr;171:9-14. Epub 2023 Feb 16 doi: 10.1016/j.ygyno.2023.01.023. PMID: 36804623
Data from small cell neuroendocrine carcinoma of the cervix: FIGO 2018 staging is more accurate than FIGO 2009.
Zhang Y, Ding J, Hua K
J Int Med Res 2022 Jan;50(1):3000605211067397. doi: 10.1177/03000605211067397. PMID: 34986672Free PMC Article
Neoadjuvant chemotherapy in pregnant patients with cervical cancer: a Latin-American multicenter study.
Lopez A, Rodriguez J, Estrada E, Aragona A, Chavez C, Amaro K, De Padua C, Borges Garnica A, Rendón G, Alméciga A, Serrano O, Scasso S, Laufer J, Greif D, Taranto F, Hoegl J, Calderaro di Ruggiero F, Pareja R
Int J Gynecol Cancer 2021 Mar;31(3):468-474. doi: 10.1136/ijgc-2020-001764. PMID: 33649015
Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I-IIB.
Zhou J, Chen Y, Xu X, Yan D, Lou H
Medicine (Baltimore) 2018 Jan;97(2):e9323. doi: 10.1097/MD.0000000000009323. PMID: 29480826Free PMC Article
Stage I and II Endometrial Adenocarcinoma: Analysis of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy.
Cahan B, Kim JH, Schultheiss TE, Wong JYC, Chen YJ
Am J Clin Oncol 2018 Mar;41(3):302-306. doi: 10.1097/COC.0000000000000273. PMID: 26886945

Therapy

Total mesometrial resection (TMMR) for cervical cancer FIGO IB-IIA: first results from the multicentric TMMR register study.
Buderath P, Stukan M, Ruhwedel W, Strutas D, Feisel-Schwickardi G, Wimberger P, Kimmig R
J Gynecol Oncol 2022 Jan;33(1):e9. Epub 2021 Dec 6 doi: 10.3802/jgo.2022.33.e9. PMID: 34910390Free PMC Article
Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer.
Maene C, Salihi RR, Van Nieuwenhuysen E, Han SN, Concin N, Vergote I
Int J Gynecol Cancer 2021 Jun;31(6):824-828. Epub 2021 Apr 15 doi: 10.1136/ijgc-2021-002432. PMID: 33858952
Neoadjuvant chemotherapy in pregnant patients with cervical cancer: a Latin-American multicenter study.
Lopez A, Rodriguez J, Estrada E, Aragona A, Chavez C, Amaro K, De Padua C, Borges Garnica A, Rendón G, Alméciga A, Serrano O, Scasso S, Laufer J, Greif D, Taranto F, Hoegl J, Calderaro di Ruggiero F, Pareja R
Int J Gynecol Cancer 2021 Mar;31(3):468-474. doi: 10.1136/ijgc-2020-001764. PMID: 33649015
Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.
Huang H, Feng YL, Wan T, Zhang YN, Cao XP, Huang YW, Xiong Y, Huang X, Zheng M, Li YF, Li JD, Chen GD, Li H, Chen YL, Ma LG, Yang HY, Li L, Yao SZ, Ye WJ, Tu H, Huang QD, Liang LZ, Liu FY, Liu Q, Liu JH
JAMA Oncol 2021 Mar 1;7(3):361-369. doi: 10.1001/jamaoncol.2020.7168. PMID: 33443541Free PMC Article
The Selection of Time Interval Between Surgery and Adjuvant Therapy in Early Stage Cervical Cancer.
You KY, Zhou XH, Jiang YH, Bi ZF, Liu YM, Qiu XS
Int J Gynecol Cancer 2018 Sep;28(7):1325-1332. doi: 10.1097/IGC.0000000000001307. PMID: 30074519Free PMC Article

Prognosis

Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study.
Duan H, Li H, Kang S, Zhao H, Chen B, Wang L, Li P, Wang Y, Wang W, Lang J, Liu P, Chen C
Acta Obstet Gynecol Scand 2023 Aug;102(8):1045-1052. Epub 2023 Jun 20 doi: 10.1111/aogs.14612. PMID: 37338046Free PMC Article
Analysis of Lymph Node Metastasis and Risk Factors in 975 Patients with FIGO 2009 Stage IA-IIA Cervical Cancer.
Cao L, Kong W, Li J, Song D, Jin B, Liu T, Han C
Gynecol Obstet Invest 2023;88(1):30-36. Epub 2022 Nov 30 doi: 10.1159/000527712. PMID: 36450266
Prognostic factors of 2018 FIGO stage IB-IIA cervical cancer with absence of high/ intermediate surgical-pathological risk factors.
Shibuya Y, Shimada M, Tsuji K, Shigeta S, Tanase Y, Matsuo K, Yamaguchi S, Kanao H, Saito T, Mikami M
Jpn J Clin Oncol 2022 Nov 3;52(11):1289-1296. doi: 10.1093/jjco/hyac125. PMID: 35913375
Preoperative high-dose-rate brachytherapy for high-risk early-stage cervical cancer: Long-term clinical outcome analysis.
Gauci PA, Kee DLC, Thamphya B, Schiappa R, Delotte J, Chand-Fouche ME, Hannoun-Levi JM
Brachytherapy 2022 May-Jun;21(3):273-282. Epub 2022 Jan 31 doi: 10.1016/j.brachy.2021.11.007. PMID: 35094933
Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer.
Jiang Y, Gu H, Zheng X, Pan B, Liu P, Zheng M
Pathol Oncol Res 2021;27:1609946. Epub 2021 Dec 21 doi: 10.3389/pore.2021.1609946. PMID: 34992504Free PMC Article

Clinical prediction guides

Analysis of Lymph Node Metastasis and Risk Factors in 975 Patients with FIGO 2009 Stage IA-IIA Cervical Cancer.
Cao L, Kong W, Li J, Song D, Jin B, Liu T, Han C
Gynecol Obstet Invest 2023;88(1):30-36. Epub 2022 Nov 30 doi: 10.1159/000527712. PMID: 36450266
MRI radiomics combined with clinicopathologic features to predict disease-free survival in patients with early-stage cervical cancer.
Jiang X, Song J, Duan S, Cheng W, Chen T, Liu X
Br J Radiol 2022 Aug 1;95(1136):20211229. Epub 2022 May 30 doi: 10.1259/bjr.20211229. PMID: 35604668Free PMC Article
Preoperative high-dose-rate brachytherapy for high-risk early-stage cervical cancer: Long-term clinical outcome analysis.
Gauci PA, Kee DLC, Thamphya B, Schiappa R, Delotte J, Chand-Fouche ME, Hannoun-Levi JM
Brachytherapy 2022 May-Jun;21(3):273-282. Epub 2022 Jan 31 doi: 10.1016/j.brachy.2021.11.007. PMID: 35094933
Total mesometrial resection (TMMR) for cervical cancer FIGO IB-IIA: first results from the multicentric TMMR register study.
Buderath P, Stukan M, Ruhwedel W, Strutas D, Feisel-Schwickardi G, Wimberger P, Kimmig R
J Gynecol Oncol 2022 Jan;33(1):e9. Epub 2021 Dec 6 doi: 10.3802/jgo.2022.33.e9. PMID: 34910390Free PMC Article
Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer.
Jiang Y, Gu H, Zheng X, Pan B, Liu P, Zheng M
Pathol Oncol Res 2021;27:1609946. Epub 2021 Dec 21 doi: 10.3389/pore.2021.1609946. PMID: 34992504Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...